Table 2.

Representative range of antiepileptic drug (AED) doses in studies with successful monotherapy.

Number of subjects	Outcome measure	Efficacy results	Dose range
Carbamazepine
30014	Seizure-free at 26 weeks	75%	400–1200 mg
23017	Withdrawn from treatment at <52 weeks	42%	200–1400 mg
12918	Seizure-free at 48 weeks	38%	300–1400 mg
23620	Seizure-free at 48–96 weeks	34%	Mean: 722 mg
10121	Withdrawn from treatment at <36 months	45%	600 mg
Lamotrigine
24942	Seizure-free at 12 months	61%	25–600 mg
22619	Seizure-free at 7 weeks	60%	100–200 mg
15637	Remaining on monotherapy	56%	100–500 mg
22243	Seizure-free at 1 year	89%	50–150 mg
13118	Seizure-free at 40 weeks	26%	100–300 mg
Phenobarbital
12453	Resolution of all clinical and electrical evidence of seizure activity within 20 minutes of start of infusion	58%	15 mg/kg
1854	Resolution of status epilepticus	61%	5–23 mg/kg
856	Fewer seizures than clorazepate comparator	50%	148 ± 21. 8 mg/day
Phenytoin
114e-ref 61	>50% seizure reduction	57%	200–300 mg
50e-ref 64	Seizure-free at 6 months	53%	3–5 mg/kg
26e-ref 65	Seizure-free at 12–41 months	76%	200–300 mg
37e-ref 66	>50% reduction in seizure frequency at 14–24 months	82%	300 mg
95e-ref 67	Seizure-free at 10 months	24%	300 mg (mode)
Valproate
238e-ref 75	Time to treatment failure	Valproate significantly better than topiramate, but no significant difference between valproate and lamotrigine	200–3000 mg
16e-ref 77	Seizure-free at 12 months	25%	1000–2000 mg
6430	>50% reduction in seizure frequency at >3 months	80%	600 mg (adults); 5–10 mg/kg (children)
13e-ref 78	Reduction in seizure frequency	A statistically significant difference was observed between VPA levels and seizure frequency. The relationship was curvilinear.	300–4000 mg
10e-ref 79	>50% reduction in seizure frequency at 12 weeks	50%	900 mg